TITLE

Continuous-Use Ethinylestradiol/Levonorgestrel 20μg/90μg as an Oral Contraceptive

AUTHOR(S)
Bednarek, Paula
PUB. DATE
October 2007
SOURCE
Drugs;2007, Vol. 67 Issue 16, p2478
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article relates the author's perspective on the use of Ethinylestradiol/Levonorgestrel 20µgram/90µgram as an oral contraceptive. She remarks that the contraceptive is the first combination oral hormonal contraceptive for continuous daily use, without hormone-free days or placebo. She contends that the cumulative monthly dose of the formulation may actually be equal to or lower than that in many other formulations of oral hormonal contraceptives, given the low dose per tablet.
ACCESSION #
31828935

 

Related Articles

  • Lamotrigine:hormonal contraceptives decrease serum levels.  // WHO Drug Information;2004, Vol. 18 Issue 4, p274 

    Reports on the announcement of the manufacturer of lamotrigine, an anti-epileptic, on the importance of new safety information concerning concomitant use of hormonal contraceptives with lamotrigine. Impact of lamotrigine on levonorgestrel plasma and ethinylestradiol concentrations; Evaluation on...

  • Microgynon 30. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p506 

    An encyclopedia entry for "Microgynon 30" is presented. It is a brand-named oral contraceptive containing the female hormones ethinyl estradiol and levonorgestrel, or a progesterone.

  • Continuous-Use Ethinylestradiol/Levonorgestrel 20μg/90μg: As an Oral Contraceptive. Wagstaff, Antona J. // Drugs;2007, Vol. 67 Issue 16, p2473 

    ▴ The continuous-use combination oral contraceptive ethinylestradiol/levonorgestrel 20μg/90μg suppresses gonadotropins, and subsequently ovulation and endometrial thickening, and suppresses breakthrough bleeding. ▴ Amenorrhoea and absence of breakthrough bleeding increase in...

  • Ethinylestradiol/levonorgestrel.  // Reactions Weekly;9/15/2007, Issue 1169, p15 

    The article describes the case of a 45-year-old woman who developed peliosis hepatitis during long-term oral contraceptive use with ethinylestradiol/levonorgestrel. The patient, who had been using the contraceptives for 9 years, was admitted with a diagnosis of urinary sepsis. An abdominal...

  • Progestins and Risk of Venous Thromboembolism: What's the Deal with Drospirenone? Micks, Elizabeth; Edelm, Alison // OB/GYN Clinical Alert;Aug2011, Vol. 28 Issue 4, p25 

    The risk of venous thromboembolism was significantly higher for users of combined oral contraceptives containing drospirenone compared to users of pills containing levonorgestrel.

  • 91-Day Extended-Regimen OC with Low-Dose EE Has No Negative Effect on Endometrium.  // Fertility Weekly;3/3/2008, p8 

    The article reports on the findings of the study concerning the effects of a 91-day extended-regimen oral contraceptive (OC) containing low-dose ethinyl estradiol (EE) on the endometrium. The study, conducted by researchers Freedolph D. Anderson and colleagues in the U.S., obtained a total of 63...

  • Levonorgestrel/Ethinyl Continuous OC Effectively Inhibits Ovulation.  // Fertility Weekly;11/9/2009, p2 

    The article presents a study that investigates the effectiveness of oral levonorgestrel (LNG)/ethinyl estradiol (EE) contraceptives in inhibiting ovulation and ovarian activity among American women. The study was conducted by David F. Archer to 58 women who received oral LNG for three 28-day...

  • Occurrence of Menses or Pregnancy after Cessation of Continuous Oral Contraceptive. Davis, Anne R. // Fertility Weekly;6/9/2008, p8 

    The article reports on the study which investigates the occurrence of menses or pregnancy after cessation of continuous oral contraceptives, levonorgestrel (LNG) and ethinyl E2 (EE). The investigation of 198 women who had stopped taking LNG and EE shows that the return to menses or pregnancy...

  • Safety of a New Oral Contraceptive Containing Drospirenone. Heinemann, Lothar A.J.; Dinger, Jürgen // Drug Safety;2004, Vol. 27 Issue 13, p1001 

    New chemical entities must undergo rigorous, and preferably independent, safety and efficacy assessments before entry into the market. This is also true for oral contraceptives (OCs) given their extensive usage by healthy women and the safety concerns highlighted by the so-called ‘third...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics